Market revenue in 2023 | USD 160.5 million |
Market revenue in 2030 | USD 295.0 million |
Growth rate | 9.1% (CAGR from 2023 to 2030) |
Largest segment | Hereditary non-cancer testing |
Fastest growing segment | Hereditary Non-cancer Testing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.
Hereditary non-cancer testing was the largest segment with a revenue share of 86.98% in 2023. Horizon Databook has segmented the Australia hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.
5.4.6 AUSTRALIA Presence of several public & private organizations that support diagnosis and management of hereditary breast cancer in Australia is expected to drive adoption of hereditary testing solutions to detect inherited gene mutations.
Some of the key organizations operating in Australia are Breast Cancer Network Australia, Royal Australian College of General Practitioners, Raising Children Network (Australia) Limited, Cancer Australia, Australian Law Reform Commission, and Pink Hope.
Cancer Australia has laid down best practice guidelines for risk assessment and provides surveillance advice that high-risk women should follow. It comprises options of genetic testing for hereditary mutations in BRCA1/BRCA2.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into Australia hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account